Alexion Shares Rise on $39 Billion AstraZeneca Deal
14 Dezember 2020 - 1:27PM
Dow Jones News
By Colin Kellaher
Alexion Pharmaceuticals Inc. shares rose more than 30% in
premarket trading Monday after the biopharmaceutical company agreed
to be acquired by U.K. drugmaker AstraZeneca PLC for $39 billion in
cash and stock.
The deal values Boston-based Alexion at $175 a share, a nearly
45% premium to Friday's closing price of $120.98.
AstraZeneca will pay $60 in cash and 2.1243 American depositary
shares for each Alexion share in the deal, slated to close in the
third quarter of 2021.
Alexion shares were recently up 31.8% to $159.50 in premarket
trading. AstraZeneca's U.K.-listed shares slipped 6.6%.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 14, 2020 07:12 ET (12:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
